Glutathione vs NAC: How They Differ

Glutathione and N-acetylcysteine (commonly abbreviated NAC) are discussed together because both are sulfur-containing compounds tied to the same biochemical pathway. They are not the same substance, they are not regulated the same way in the United States, and the human research behind each is structured differently. This page compares them on four axes: head-to-head data, composition and mechanism, the human trial literature that exists for each, and regulatory status plus what the cited reports describe regarding safety. A general introduction to glutathione itself sits on the glutathione glossary entry and the guide to what glutathione is used for. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Head-to-head trials: what the cited literature contains

No randomized controlled trial in the verified citation set assigned one group to glutathione and another group to NAC and then compared the two against a shared primary endpoint. That absence matters, because without a direct comparison there is no measured difference in effect size between the two compounds to report, and any claim that one outperforms the other would not be supported by the literature summarized here.

The closest design is a randomized clinical trial in older adults that supplemented glycine together with N-acetylcysteine, a combination the authors abbreviated GlyNAC, in which researchers reported improvements in glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function and aging hallmarks relative to the comparison condition (PMID 35975308). That design compared a two-amino-acid combination with a control condition rather than comparing NAC with glutathione, so the study does not isolate NAC on its own and does not place glutathione supplementation in a competing arm (PMID 35975308).

Where head-to-head data are missing, the remaining option is to lay the separate evidence bases next to each other and let the differences in study design, population and endpoint stay visible. That is the approach taken below.

Composition and structure

Glutathione is a tripeptide assembled from three amino acids: glutamate, cysteine and glycine. The cysteine residue carries the thiol group that gives the molecule its redox chemistry. NAC is not a peptide at all; it is N-acetyl-L-cysteine, a single amino acid derivative in which an acetyl group is attached to the nitrogen of cysteine. The acetyl group changes the stability and handling characteristics of cysteine, and the molecule is widely described as a cysteine precursor rather than as glutathione itself.

The structural logic behind combining NAC with glycine in the GlyNAC trial follows directly from this difference: two of the three amino acids that make up glutathione were supplied, and the trial was framed around correcting glutathione deficiency in older adults (PMID 35975308). In short, NAC is not a smaller version of glutathione and glutathione is not a bulk form of NAC; one is an intact tripeptide, the other is a precursor to one of its three components.

How NAC relates to glutathione synthesis

Cysteine availability is the component most often described as limiting in glutathione synthesis, which is why NAC appears in studies that measure glutathione as an outcome rather than as the intervention. A preliminary magnetic resonance spectroscopy study in schizophrenia measured brain glutathione and glutamate in relation to N-acetylcysteine administration, and the authors described the work as preliminary in both sample size and interpretation (PMID 35839558). In the GlyNAC trial, glutathione deficiency in older adults was itself a stated target and researchers reported improvement in that measure alongside oxidative stress and mitochondrial markers (PMID 35975308).

NAC chemistry is not confined to glutathione. One 2022 study reported that N-acetylcysteine regenerated mercaptoalbumin in vivo, pointing to thiol pools outside the glutathione system (PMID 36139832). A review of N-acetylcysteine and hydrogen sulfide in coronavirus disease 2019 similarly discussed sulfur signalling pathways rather than glutathione concentration alone (PMID 33607929). Readers comparing the two compounds should note that "raises glutathione" is only one of several mechanisms attributed to NAC in the cited literature.

Side-by-side comparison

Human trial evidence for NAC

Psychiatry and neurology

A phase III, 20-week, double-blind, randomized, placebo-controlled trial examined N-acetyl cysteine augmentation in the treatment of obsessive-compulsive disorder, with randomization to augmentation or placebo on top of existing treatment (PMID 35304155). In mood disorders, a randomized placebo-controlled study evaluated the efficacy of adjunctive N-acetylcysteine in acute bipolar depression (PMID 30699846). In autism spectrum disorders, a meta-analysis pooled randomized controlled trials to assess the effectiveness of N-acetylcysteine across the available trial literature (PMID 32900213). In Parkinson's disease, a clinical study reported that N-acetyl cysteine was associated with dopaminergic improvement (PMID 31206613). The schizophrenia imaging work described above measured glutathione and glutamate rather than clinical response and was labelled preliminary by its authors (PMID 35839558).

Respiratory and infectious disease

A 2024 trial published in NEJM Evidence examined adjunctive N-acetylcysteine and lung function in pulmonary tuberculosis, with lung function as the outcome of interest alongside standard tuberculosis treatment (PMID 39189858). In coronavirus disease 2019, a 2025 systematic review and meta-analysis of randomized controlled trials assessed the effect of N-acetylcysteine on mortality (PMID 40728675), while an earlier review discussed proposed mechanisms involving hydrogen sulfide (PMID 33607929).

Perioperative medicine

A 2024 review of perioperative N-acetylcysteine summarized the evidence and the indications discussed in that setting, collecting trial data across surgical contexts rather than reporting a single new randomized comparison (PMID 39166871).

Human evidence for glutathione in this citation set

Within the verified papers summarized here, glutathione appears as a measured biological variable rather than as an administered intervention. The GlyNAC trial targeted glutathione deficiency in older adults and researchers reported changes in that marker along with oxidative stress, mitochondrial function, inflammation and physical function measures (PMID 35975308), and the magnetic resonance spectroscopy study measured glutathione in brain tissue in relation to NAC (PMID 35839558). That asymmetry is itself a finding worth stating plainly: the comparison question is often framed as if two interchangeable supplements were competing, while the trial literature cited here mostly administers NAC and measures glutathione.

Regulatory status in the United States

Oral glutathione is sold in the United States as a dietary supplement. Dietary supplements are not approved by the FDA for efficacy before they reach the market, and the manufacturer, not the agency, is responsible for substantiating label claims. No glutathione product has FDA approval for skin lightening. Injectable and intravenous glutathione preparations are not FDA-approved drug products in the United States; intravenous administration appears in this literature only as a study design feature or as the subject of regulatory warnings, and no page content here describes administration.

Acetylcysteine occupies a different regulatory position. It is the active ingredient in FDA-approved prescription drug products, including an inhalation solution used as a mucolytic adjuvant and formulations used in the management of acetaminophen overdose. Those approvals apply to specific prescription products with specific labelling, and they are separate from NAC sold in supplement form. A prescription approval for one formulation and indication does not transfer to supplement products, to other indications, or to glutathione.

Adverse Events: What Studies Report

The verified papers do not provide a standardized, head-to-head safety comparison between glutathione and NAC, so no side-by-side adverse event table can be constructed from them. What exists is safety information embedded in individual trial designs: the phase III obsessive-compulsive disorder trial ran a 20-week double-blind placebo-controlled protocol in which tolerability was tracked alongside efficacy (PMID 35304155), the bipolar depression study used a placebo-controlled adjunctive design that allowed comparison of complaints between arms (PMID 30699846), and the tuberculosis trial added N-acetylcysteine to standard treatment, a setting in which interactions with concurrent therapy are monitored (PMID 39189858). The perioperative review discussed indications alongside the practical considerations clinicians weigh in surgical settings (PMID 39166871).

Separate from the research literature, FDA-approved acetylcysteine prescription labelling describes hypersensitivity reactions, including anaphylactoid reactions associated with intravenous administration, and bronchospasm associated with inhalation use. Those are label-level product facts for prescription drugs and are not statements about supplement products or about glutathione. Interaction questions are covered on the glutathione interactions guide.

How to read this comparison

Several points follow from the material above. First, volume of evidence is not a quality ranking: NAC appears in more of the cited trials than glutathione does, which reflects what investigators chose to administer rather than a measured superiority. Second, trials that report positive signals, such as the association between N-acetyl cysteine and dopaminergic improvement in Parkinson's disease (PMID 31206613), sit beside pooled analyses in other conditions that weigh heterogeneous studies together (PMID 32900213, PMID 40728675). Third, combination designs complicate attribution, as the glycine plus NAC trial illustrates (PMID 35975308). Doses used in any cited trial belong to that trial's design and are not reproduced here as guidance.

Related reading

• Glutathione glossary entry
• What is glutathione used for
• Glutathione interactions

References

• Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial (The Journals of Gerontology Series A, 2023)
• Effectiveness of N-acetylcysteine in autism spectrum disorders: A meta-analysis of randomized controlled trials (Australian and New Zealand Journal of Psychiatry, 2021)
• N-Acetylcysteine Regenerates In Vivo Mercaptoalbumin (Antioxidants, 2022)
• Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis (NEJM Evidence, 2024)
• Perioperative N-acetylcysteine: evidence and indications (Pain Management, 2024)
• N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease (Clinical Pharmacology and Therapeutics, 2019)
• The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study (Journal of Affective Disorders, 2019)
• N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study (Psychiatry Research: Neuroimaging, 2022)
• N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022)
• N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019 (Antioxidants and Redox Signaling, 2021)
• Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials (Inflammopharmacology, 2025)